# ABCD liraglutide audit HbA1c changes according to duration of diabetes

Figure 2. Mean HbA1c changes after 26 weeks of liraglutide treatment, stratified according to duration of diabetes

Columns show adjusted mean changes analysed by ANCOVA with baseline HbA1c as a covariate. ED: estimated difference; CI: confidence interval

Estimated change in HbA$_{1c}$ and body weight by baseline diabetes duration

Diabetes duration	≤5 years				>5 to ≤10 years				>10 years			
Change from baseline:	HbA$_{1c}$ (%)		Body weight (kg)		HbA$_{1c}$ (%)		Body weight (kg)		HbA$_{1c}$ (%)		Body weight (kg)	
N	533	641	533	641	423	565	423	565	376	528	376	528
Baseline	8.1	8.1	95.9	95.9	8.2	8.2	93.5	93.5	8.3	8.3	89.8	89.8
End of treatment	6.6	6.4	91.8	90.1	6.8	6.4	89.6	87.7	6.8	6.5	85.8	84.1

Change from baseline in HbA$_{1c}$ (%-point)

Change from baseline in BW (kg)

≤5 years: -1.4, -1.7, -4.1, -5.7
>5 to ≤10 years: -1.4, -1.8, -3.8, -5.8
>10 years: -1.5, -1.7, -3.9, -5.7

Semaglutide 0.5 mg (HbA$_{1c}$, %)
Semaglutide 1.0 mg (HbA$_{1c}$, %)
Semaglutide 0.5 mg (Body weight, kg)
Semaglutide 1.0 mg (Body weight, kg)